TapewireFind a company

person · Reporting owner

LINK WILLIAM J PHD

Disclosed activity across 7 companies

Tapewire entity
34847
SEC CIK
0001228684

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Edwards Lifesciences CorpEW · Entity 3026DirectorMay 08, 2020May 11, 2020
GLAUKOS CorpGKOS · Entity 3510DirectorJune 03, 2021June 07, 2021
LENSAR, Inc.LNSR · Entity 6733DirectorJune 03, 2026June 05, 2026
Oyster Point Pharma, Inc.OYST · Entity 15903DirectorJanuary 05, 2022January 07, 2022
RxSight, Inc.RXST · Entity 1226DirectorJune 17, 2026June 18, 2026
Tarsus Pharmaceuticals, Inc.TARS · Entity 1836DirectorSeptember 15, 2026September 17, 2026
Vivani Medical, Inc.EYES · Entity 6636DirectorJune 04, 2019June 05, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Edwards Lifesciences Corp

Report date May 08, 2020 · Filed May 11, 2020

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect11,349 Ending reported balance After 2020-05-08 transaction · row 2
2 source rows · reconciled sequence

Row 1 · 2020-05-08 · Grant · Acquired 1,101 · Balance 11,004

F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

Row 2 · 2020-05-08 · Grant · Acquired 345 · Balance 11,349

F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

Common StockSEC Table I · non-derivativeIndirectLink Family Enterprise, LP4,722 Reported balance Holding disclosure · report date 2020-05-08 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 4,722

Common StockSEC Table I · non-derivativeIndirectLink Family Trust6,050 Reported balance Holding disclosure · report date 2020-05-08 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 6,050

Filing footnotes · ownership attribution and instrument terms

F1: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

F2: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

GLAUKOS Corp

Report date June 03, 2021 · Filed June 07, 2021

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect17,821 Reported balance After 2021-06-03 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2021-06-03 · Grant · Acquired 2,382 · Balance 17,821

F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Common StockSEC Table I · non-derivativeIndirectSee footnote40,479 Reported balance Holding disclosure · report date 2021-06-03 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 40,479

F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2: Includes 2,382 restricted stock units that have not yet vested or been delivered to the Reporting Person.

F3: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

LENSAR, Inc.

Report date June 03, 2026 · Filed June 05, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect568,062 Reported balance After 2026-06-03 transaction · row 1
1 source row

Row 1 · 2026-06-03 · Grant · Acquired 17,421 · Balance 568,062

F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of LENSAR, Inc. common stock. The RSUs vest in full on June 3, 2027, subject to the Reporting Person's continued service to the Issuer through the vesting date, and will be settled upon the earliest to occur of (a) the Reporting Person's termination of service, (b) a change in control of the Company, or (c) the Reporting Person's death or disability. The RSUs were granted in accordance with the Issuer's non-employee director compensation program as a component of the Reporting Person's annual compensation for service to the Issuer.

Oyster Point Pharma, Inc.

Report date January 05, 2022 · Filed January 07, 2022

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectBy Limited Partnership33,480 Reported balance After 2022-01-05 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2022-01-05 · Other · Acquired 6,438 · Balance 33,480

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.

F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

Common StockSEC Table I · non-derivativeIndirectBy Trust2,074 Reported balance After 2022-01-05 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2022-01-05 · Other · Acquired 401 · Balance 2,074

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration.

F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.

Common StockSEC Table I · non-derivativeIndirectBy LLC27,942 Reported balance Holding disclosure · report date 2022-01-05 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 27,942

F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.

Common StockSEC Table I · non-derivativeDirect10,066 Reported balance Holding disclosure · report date 2022-01-05 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 10,066

Common StockSEC Table I · non-derivativeIndirectSee Footnote2,465 Reported balance Holding disclosure · report date 2022-01-05 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 2,465

F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Common StockSEC Table I · non-derivativeIndirectSee Footnote414,607 Reported balance Holding disclosure · report date 2022-01-05 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 414,607

F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.

F2: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

F3: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration.

F4: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.

F5: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.

F6: Shares held by Versant Side Fund IV following its distribution to the Reporting Person reported herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Versant Side Fund IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Versant Side Fund IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F7: Shares held by Capital IV following its distribution to the Reporting Person herein and its other members. The Reporting Person may be deemed to beneficially own the shares held by Capital IV as a managing member of Ventures IV, its sole general partner. The Reporting Person disclaims beneficial ownership of the securities held by Capital IV except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

RxSight, Inc.

Report date June 17, 2026 · Filed June 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect74,892 Reported balance After 2026-06-17 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-06-17 · Grant · Acquired 37,037 · Balance 74,892

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

Common StockSEC Table I · non-derivativeIndirectSee footnote21,248 Reported balance Holding disclosure · report date 2026-06-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 21,248

F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of RxSight, Inc. Common Stock.

F2: Subject to the Reporting Person's continuing as an Outside Director (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the RSUs subject to the award shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the date of the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 17, 2026.

F3: Shares held by Link Family Enterprise, L.P. The Reporting Person is a managing partner of Link Family Enterprise, L.P. and may be deemed to share voting and investment power over the securities held by Link Family Enterprise, L.P. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his respective pecuniary interests therein.

Tarsus Pharmaceuticals, Inc.

Report date September 15, 2026 · Filed September 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect94,487 Ending reported balance After 2026-09-15 transaction · row 4
4 source rows · reconciled sequence

Row 1 · 2026-09-15 · Exercise / conversion · Acquired 201 · Balance 106,987

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

Row 2 · 2026-09-15 · Sale · Disposed 11,675 · Balance 95,312

F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 3 · 2026-09-15 · Sale · Disposed 759 · Balance 94,553

F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Row 4 · 2026-09-15 · Sale · Disposed 66 · Balance 94,487

F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect605 Reported balance After 2026-09-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2026-09-15 · Exercise / conversion · Disposed 201 · Balance 605

F5: Each RSU represents a contingent right to receive one share of the Company's common stock.

F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Filing footnotes · ownership attribution and instrument terms

F1: The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.

F2: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 8, 2025.

F3: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $77.87 to $78.86. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $78.89 to $79.10. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: Each RSU represents a contingent right to receive one share of the Company's common stock.

F6: RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The RSUs vest in equal installments on 9/15/2026, 12/15/2026, 3/15/2027 and 6/15/2027, subject to the non-employee director's continuous service.

Vivani Medical, Inc.

Report date June 04, 2019 · Filed June 05, 2019

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Non-Qualified Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.71 · Expires 2029-06-04Direct56,685 Reported balance After 2019-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2019-06-04 · Grant · Acquired 56,685 · Balance 56,685

F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting.

F2: Awarded as compensation for serving on the Board of Directors and its committees.

Filing footnotes · ownership attribution and instrument terms

F1: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting.

F2: Awarded as compensation for serving on the Board of Directors and its committees.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
May 12, 2021 Filed May 14, 2021 20:42 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 10,302 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-032758 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Limited Partnership

Disclosed balance after: 20,604

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.

F2 · ownership.nature: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

Read SEC document
March 26, 2021 Filed Mar 31, 2021 01:45 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 631 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-023694 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 631

F3 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Side Fund IV, L.P. ("Versant Side Fund IV") to The Link Family Trust, dated May 19, 2005, without consideration.

F4 · ownership.nature: Shares held by The Link Family Trust. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the Trustee of The Link Family Trust.

Read SEC document
March 26, 2021 Filed Mar 31, 2021 01:45 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 10,302 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-023694 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Limited Partnership

Disclosed balance after: 10,302

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Versant Venture Capital IV, L.P. ("Capital IV") to Versant Ventures IV, LLC ("Ventures IV"), its sole general partner, without consideration, and from Ventures IV to Link Family Enterprise, LP as a member of Ventures IV.

F2 · ownership.nature: Shares held by Link Family Enterprise, LP. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Link Family Enterprise, LP.

Read SEC document
December 10, 2020 Filed Dec 15, 2020 01:45 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 27,942 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-063362 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 27,942

F3 · kind: Represents the acquisition of the shares of Common Stock of the Issuer by Flying L Partners VII, LLC in connection with the pro-rata distribution described in footnote (1) herein.

F4 · ownership.nature: Shares held by Flying L Partners VII, LLC. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Flying L Partners VII, LLC.

Read SEC document
December 10, 2020 Filed Dec 15, 2020 01:45 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 OtherCommon Stock 955,392 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-063362 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: Represents a pro-rata in-kind distribution of Common Stock of the Issuer by Oyster Point Pharma I, LLC, without consideration, to its members.

F2 · ownership.nature: Shares originally held by Oyster Point Pharma I, LLC. The Reporting Person may have been deemed to have beneficially owned the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, LLC.

Read SEC document
December 07, 2020 Filed Dec 11, 2020 01:53 UTC LENSAR, Inc. LNSR · Entity 6733 GrantCommon Stock 80,157 $0.00 $0.00
Disclosure

SEC source: 0000899243-20-033401 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,694

F1 · shares: Represents restricted stock awarded to the Reporting Person on December 7, 2020 in connection with an amendment on the same date to the restricted stock awarded to him on July 22, 2020 to amend and extend the vesting schedule applicable to such award (the "Original Award"). In order to comply with tax laws and to recognize the Reporting Person's agreement to an extension of the overall vesting schedule of the Original Award, the Reporting Person was issued the restricted stock award, which represents 20% of the total number of shares subject to the Original Award. The restricted stock award will vest on the same amended vesting schedule applicable to the Original Award, which amended vesting schedule provides for vesting in quarterly installments over the approximately three-year period following the amendment date.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionStock Option (Right to Buy) · Derivative 15,000 $0.00 Strike: $24.69 $0.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · derivative · entry 9

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,000 shares

Expires 2026-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Granted June 2, 2016 pursuant to the Issuer's 2015 Omnibus Incentive Compensation Plan. Vests in full on the one-year anniversary of the grant date.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $32.00 $0.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · derivative · entry 8

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-07-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: Granted on July 23, 2015 pursuant to the Issuer's 2015 Stock Plan. Vests annually over a three-year period such that it is vested in full on the three-year anniversary of the grant date.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $7.28 $0.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · derivative · entry 7

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2024-07-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Granted July 10, 2014 pursuant to the Issuer's 2011 Stock Plan. Vests annually over a three-year period such that it is vested in full on the three-year anniversary of the grant date.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 SaleCommon Stock 600 $68.72 $41,231.82
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 5

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,439

F3 · price: This transaction was executed in multiple trades at prices ranging from $68.68 to $68.785. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 SaleCommon Stock 49,400 $67.96 $3,357,090.62
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 4

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,039

F2 · price: This transaction was executed in multiple trades at prices ranging from $67.68 to $68.675. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionCommon Stock 15,000 $24.69 $370,350.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionCommon Stock 25,000 $32.00 $800,000.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
December 01, 2020 Filed Dec 4, 2020 01:39 UTC GLAUKOS Corp GKOS · Entity 3510 Exercise / conversionCommon Stock 10,000 $7.28 $72,750.00
Disclosure

SEC source: 0001104659-20-132117 · a4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,439

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:57 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionSeries B Preferred Stock · Derivative 1,112,301 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055422 · doc4.xml · derivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flying L Investments XI, LLC

Disclosed balance after: 0

Underlying: Common Stock · 1,112,301 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.exercise_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F1 · derivative.expiration_date: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held directly held by Flying L Investments XI, LLC. The Reporting Person is the manager of Flying L Investments XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Read SEC document
October 20, 2020 Filed Oct 20, 2020 23:57 UTC Tarsus Pharmaceuticals, Inc. TARS · Entity 1836 ConversionCommon Stock 1,112,301 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-20-055422 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By Flying L Investments XI, LLC

Disclosed balance after: 1,112,301

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into shares of the Issuer's common stock, par value $0.0001 per share, on a one-for-one basis. The shares of Preferred Stock had no expiration date.

F2 · ownership.nature: The shares are held directly held by Flying L Investments XI, LLC. The Reporting Person is the manager of Flying L Investments XI, LLC and may be deemed to have sole voting and investment power over the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.

Read SEC document
June 08, 2020 Filed Jun 11, 2020 01:15 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 GrantCommon Stock 6,600 $0.00 $0.00
Disclosure

SEC source: 0001209191-20-035748 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,600

F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.

F2 · shares: The shares underlying the RSU vest as to one-twelfth (1/12th) of the RSU on July 8, 2020 and monthly thereafter on the same day of the month as the grant date; however, the shares underlying the RSU will vest fully on the date of the next annual stockholder meeting held after the date of grant if not fully vested on such date, in each case, subject to the Reporting Person's continuous service to the Issuer as a director through each such date.

Read SEC document
June 03, 2020 Filed Jun 6, 2020 01:21 UTC GLAUKOS Corp GKOS · Entity 3510 GrantCommon Stock 3,900 $0.00 $0.00
Disclosure

SEC source: 0001127602-20-019057 · form4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,439

F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2 · balance_after: Includes 6,013 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
May 08, 2020 Filed May 11, 2020 18:12 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 345 $0.00 $0.00
Disclosure

SEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,349

F2 · shares: This restricted stock was granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

Read SEC document
May 08, 2020 Filed May 11, 2020 18:12 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 1,101 $0.00 $0.00
Disclosure

SEC source: 0001225208-20-007365 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,004

F1 · shares: These restricted stock units were granted on May 8, 2020 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

Read SEC document
January 02, 2020 Filed Jan 3, 2020 21:31 UTC GLAUKOS Corp GKOS · Entity 3510 GrantCommon Stock 2,113 $0.00 $0.00
Disclosure

SEC source: 0001104659-20-000905 · a4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,539

F1 · security: Represents a grant of restricted stock units received by the reporting person in lieu of annual director retainer fees pursuant to a stock-for-fees election under the Issuer's Director Compensation Policy. The units will vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2 · balance_after: Includes 4,766 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionSeries B Convertible Preferred Stock · Derivative 955,392 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 7

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 955,392 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.nature: Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionSeries A Convertible Preferred Stock · Derivative 1,654,359 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 6

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 1,654,359 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV").

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionSeries A Convertible Preferred Stock · Derivative 10,420 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · derivative · entry 5

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 0

Underlying: Common Stock, par value $0.001 per share · 10,420 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.exercise_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F1 · derivative.expiration_date: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionCommon Stock, par value $0.001 per share 955,392 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 4

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 955,392

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F5 · ownership.nature: Shares held by Oyster Point Pharma I, L.L.C. The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person as the controlling member of Oyster Point Pharma I, L.L.C.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 PurchaseCommon Stock, par value $0.001 per share 27,500 $16.00 $440,000.00
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 2,002,298

F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV").

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionCommon Stock, par value $0.001 per share 1,654,359 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 1,974,798

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F3 · ownership.nature: Shares held by Versant Venture Capital IV, L.P. ("Versant IV").

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
November 04, 2019 Filed Nov 4, 2019 22:51 UTC Oyster Point Pharma, Inc. OYST · Entity 15903 ConversionCommon Stock, par value $0.001 per share 10,420 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-19-026595 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 12,438

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: These shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, "Preferred Stock") automatically converted into shares of the Issuer's common stock, $0.001 par value per share ("Common Stock"), on a one-for-one basis, immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date.

F2 · ownership.nature: Shares held by Versant Side Fund IV, L.P. ("Versant Side Fund IV").

F4 · ownership.nature: The Reporting Person may be deemed to beneficially own the shares indirectly by reason of the Reporting Person is a managing member of Versant Ventures IV, LLC, the sole general partner of Versant IV and Versant Side Fund IV. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person, as applicable, is the beneficial owner of, or has any pecuniary interest in, such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Read SEC document
August 21, 2019 Filed Aug 21, 2019 21:59 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 1,650 $222.02 $366,327.89
Disclosure

SEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Link Family Enterprise, LP

Disclosed balance after: 4,722

Read SEC document
August 21, 2019 Filed Aug 21, 2019 21:59 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 6,914 $221.56 $1,531,861.69
Disclosure

SEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,903

F1 · price: This transaction was executed in multiple trades at prices ranging from $221.17 to $222.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
August 20, 2019 Filed Aug 21, 2019 21:59 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 1,650 $222.98 $367,918.98
Disclosure

SEC source: 0001225208-19-011800 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,817

Read SEC document
June 04, 2019 Filed Jun 5, 2019 20:15 UTC Vivani Medical, Inc. EYES · Entity 6636 GrantNon-Qualified Stock Option(right to buy) · Derivative 56,685 $0.00 Strike: $0.71 $0.00
Disclosure

SEC source: 0001209191-19-034727 · doc4.xml · derivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,685

Underlying: Common Stock · 56,685 shares

Expires 2029-06-04

F1 · derivative.exercise_date: The stock options have a 10-year term and fully vest on the earlier of annual grant date anniversary or the date of the next annual shareholder's meeting.

F2 · derivative.underlying_shares: Awarded as compensation for serving on the Board of Directors and its committees.

Read SEC document
May 30, 2019 Filed Jun 1, 2019 00:07 UTC GLAUKOS Corp GKOS · Entity 3510 GrantCommon Stock 2,653 $0.00 $0.00
Disclosure

SEC source: 0001104659-19-033246 · a4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,426

F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2 · balance_after: Includes 4,793 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
May 09, 2019 Filed May 13, 2019 22:35 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 414 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,467

F2 · shares: This restricted stock was granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested on March 15, 2020.

Read SEC document
May 09, 2019 Filed May 13, 2019 22:35 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 1,323 $0.00 $0.00
Disclosure

SEC source: 0001225208-19-007860 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,053

F1 · shares: These restricted stock units were granted on May 9, 2019 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the director ceases to serve on Issuer's Board.

Read SEC document
January 02, 2019 Filed Jan 16, 2019 21:28 UTC GLAUKOS Corp GKOS · Entity 3510 GrantCommon Stock 2,140 $0.00 $0.00
Disclosure

SEC source: 0001562180-19-000314 · primarydocument.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,773

F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2 · balance_after: Consists of 6,773 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
November 19, 2018 Filed Nov 21, 2018 01:24 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 10,950 $149.88 $1,641,203.52
Disclosure

SEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 4

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Link Family Trust

Disclosed balance after: 6,050

F3 · kind: This transaction was executed in multiple trades at prices ranging from $149.68 to $150.39. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Read SEC document
November 19, 2018 Filed Nov 21, 2018 01:24 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 2,628 $150.06 $394,363.99
Disclosure

SEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Link Family Enterprise, LP

Disclosed balance after: 6,372

F1 · kind: This transaction was executed in multiple trades at prices ranging from $150.03 to $150.13. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F2 · balance_after: Includes shares that were previously aggregated with other shares reported as held indirectly.

Read SEC document
November 15, 2018 Filed Nov 15, 2018 23:28 UTC GLAUKOS Corp GKOS · Entity 3510 SaleCommon Stock 1,300 $58.18 $75,634.00
Disclosure

SEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 4

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 40,479

F4 · price: This transaction was executed in multiple trades at prices ranging from $58.10 to $58.37. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

Read SEC document
November 15, 2018 Filed Nov 15, 2018 23:28 UTC GLAUKOS Corp GKOS · Entity 3510 SaleCommon Stock 25,725 $57.37 $1,475,843.25
Disclosure

SEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 41,779

F3 · price: This transaction was executed in multiple trades at prices ranging from $57.00 to $57.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

Read SEC document
November 14, 2018 Filed Nov 15, 2018 23:28 UTC GLAUKOS Corp GKOS · Entity 3510 GiftCommon Stock 8,500 $0.00 $0.00
Disclosure

SEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 67,504

F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

Read SEC document
November 13, 2018 Filed Nov 15, 2018 23:28 UTC GLAUKOS Corp GKOS · Entity 3510 SaleCommon Stock 14,475 $58.01 $839,694.75
Disclosure

SEC source: 0001562180-18-004576 · primarydocument.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · see footnote

Disclosed balance after: 76,004

F1 · price: This transaction was executed in multiple trades at prices ranging from $58.00 to $58.045. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2 · ownership.nature: The shares are held by The Link Family Trust (the "Link Trust") for the benefit of William J. Link. William J. Link is a trustee of the Link Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his proportionate pecuniary interest therein.

Read SEC document
August 31, 2018 Filed Nov 21, 2018 01:24 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 3

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Link Family Trust

Disclosed balance after: 17,000

F2 · balance_after: Includes shares that were previously aggregated with other shares reported as held indirectly.

Read SEC document
August 31, 2018 Filed Nov 21, 2018 01:24 UTC Edwards Lifesciences Corp EW · Entity 3026 GiftCommon Stock 10,000 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-015757 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,730

Read SEC document
June 02, 2018 Filed Jun 6, 2018 01:00 UTC Vivani Medical, Inc. EYES · Entity 6636 GrantNon Qualified Stock Option (right to buy) · Derivative 25,970 $0.00 Strike: $2.05 $0.00
Disclosure

SEC source: 0001437749-18-011317 · rdgdoc.xml · derivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,970

Underlying: Common Stock · 25,970 shares

Expires 2028-06-02

F1 · derivative.underlying_shares: Awarded as compensation for serving on the Board of Directors and its committees.

Read SEC document
June 01, 2018 Filed Jun 6, 2018 01:00 UTC Vivani Medical, Inc. EYES · Entity 6636 GrantCommon Stock 34,518 $0.00 $0.00
Disclosure

SEC source: 0001437749-18-011317 · rdgdoc.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,186

F1 · shares: Awarded as compensation for serving on the Board of Directors and its committees.

Read SEC document
May 31, 2018 Filed Jun 1, 2018 20:33 UTC GLAUKOS Corp GKOS · Entity 3510 GrantCommon Stock 4,633 $0.00 $0.00
Disclosure

SEC source: 0001562180-18-002759 · primarydocument.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,633

F1 · security: Granted by the Issuer in the form of restricted stock units that vest in full on the one-year anniversary of the grant date and are payable in an equivalent number of shares of the Issuer's common stock.

F2 · balance_after: Consists of 4,633 restricted stock units that have not yet vested or been delivered to the Reporting Person.

Read SEC document
May 18, 2018 Filed May 22, 2018 23:40 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 479 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,730

F2 · shares: This restricted stock was granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program and is scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders.

Read SEC document
May 18, 2018 Filed May 22, 2018 23:40 UTC Edwards Lifesciences Corp EW · Entity 3026 GrantCommon Stock 1,655 $0.00 $0.00
Disclosure

SEC source: 0001225208-18-009753 · doc4.xml · nonDerivative · entry 1

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,251

F1 · shares: These restricted stock units were granted on May 18, 2018 under the Edwards Lifesciences Corporation Nonemployee Directors Stock Incentive Program. They are scheduled to become vested 100% after the earlier of one year from the grant date or Issuer's next annual meeting of stockholders. The underlying common stock (net of any shares sold to cover applicable taxes) must be held until the reporting person ceases to serve on Issuer's Board.

Read SEC document
February 09, 2018 Filed Feb 13, 2018 23:28 UTC Edwards Lifesciences Corp EW · Entity 3026 SaleCommon Stock 8,400 $122.08 $1,025,502.24
Disclosure

SEC source: 0001225208-18-002799 · doc4.xml · nonDerivative · entry 2

LINK WILLIAM J PHD · CIK 0001228684 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · *

Disclosed balance after: 16,000

F3 · price: This transaction was executed in multiple trades at prices ranging from $121.47 to $122.46. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

F2 · ownership.nature: Held by the Link Family Trust, dated May 31, 1990, and the Link Family Enterprise, LLC.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.